Target family: CDC7 family (type: enzyme)
Target: cell division cycle 7

Ligand: compound 18 [PMID: 20873740] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7.659999847412109 pIC50
Reference (Journal): Cdc7 kinase inhibitors: 5-heteroaryl-3-carboxamido-2-aryl pyrroles as potential antitumor agents. 1. Lead finding.
Published in: J Med Chem

Ligand: compound 1 [PMID: 24793884] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.489999771118164 pIC50
Reference (Journal): Synthesis and structure-activity relationship of trisubstituted thiazoles as Cdc7 kinase inhibitors.
Published in: Eur J Med Chem

Ligand: compound 2 [PMID: 22560567] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8.850000381469727 pIC50
Reference (Journal): Discovery of XL413, a potent and selective CDC7 inhibitor.
Published in: Bioorg Med Chem Lett

Ligand: compound 74 [PMID: 24793884] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.420000076293945 pIC50
Reference (Journal): Synthesis and structure-activity relationship of trisubstituted thiazoles as Cdc7 kinase inhibitors.
Published in: Eur J Med Chem

Ligand: compound 77 [PMID: 24793884] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.170000076293945 pIC50
Reference (Journal): Synthesis and structure-activity relationship of trisubstituted thiazoles as Cdc7 kinase inhibitors.
Published in: Eur J Med Chem

Ligand: compound 89S [PMID: 19115845] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 9.300000190734863 pKi
Reference (Journal): First Cdc7 kinase inhibitors: pyrrolopyridinones as potent and orally active antitumor agents. 2. Lead discovery.
Published in: J Med Chem

Ligand: compound 89S [PMID: 19115845] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8.699999809265137 pIC50
Reference (Journal): First Cdc7 kinase inhibitors: pyrrolopyridinones as potent and orally active antitumor agents. 2. Lead discovery.
Published in: J Med Chem

Ligand: monzosertib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.619999885559082 pIC50
Reference (Journal): Discovery of AS-0141, a Potent and Selective Inhibitor of CDC7 Kinase for the Treatment of Solid Cancers.
Published in: J Med Chem

Ligand: simurosertib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Patent): Heterocyclic compound

Ligand: XL413 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8.470000267028809 pIC50
Reference (Journal): Discovery of XL413, a potent and selective CDC7 inhibitor.
Published in: Bioorg Med Chem Lett